CoChat
Sign Up
Cited by 1,518Neuroscience and Neuropharmacology ResearchAmino Acid Enzymes and MetabolismNeuroprotection in Cerebral Ischemia

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

Rothstein, Jeffrey D., Patel, Sarjubhai, Regan, Melissa R., Haenggeli, Christine, Huang, Yanhua H., Bergles, Dwight E., Jin, Lin, Dykes Hoberg, Margaret, Vidensky, Svetlana, Chung, Dorothy S., Toan, Shuy Vang, Bruijn, Lucie I., Su, Zao-zhong, Gupta, Pankaj, Fisher, Paul B.·2005·Nature
DOI 10.1038/nature03180
Open this paper in CoChat — free account

Abstract

Glutamate is the principal excitatory neurotransmitter in the nervous system. Inactivation of synaptic glutamate is handled by the glutamate transporter GLT1 (also known as EAAT2; refs 1, 2), the physiologically dominant astroglial protein. In spite of its critical importance in normal and abnormal synaptic activity, no practical pharmaceutical can positively modulate this protein. Animal studies show that the protein is important for normal excitatory synaptic transmission, while its dysfunction is implicated in acute and chronic neurological disorders, including amyotrophic lateral sclerosis (ALS), stroke, brain tumours and epilepsy. Using a blinded screen of 1,040 FDA-approved drugs and nutritionals, we discovered that many beta-lactam antibiotics are potent stimulators of GLT1 expression. Furthermore, this action appears to be mediated through increased transcription of the GLT1 gene. beta-Lactams and various semi-synthetic derivatives are potent antibiotics that act to inhibit bacterial synthetic pathways. When delivered to animals, the beta-lactam ceftriaxone increased both brain expression of GLT1 and its biochemical and functional activity. Glutamate transporters are important in preventing glutamate neurotoxicity. Ceftriaxone was neuroprotective in vitro when used in models of ischaemic injury and motor neuron degeneration, both based in part on glutamate toxicity. When used in an animal model of the fatal disease ALS, the drug delayed loss of neurons and muscle strength, and increased mouse survival. Thus these studies provide a class of potential neurotherapeutics that act to modulate the expression of glutamate neurotransmitter transporters via gene activation.

Overview

Integrity signals

Registry

Crossref · 10.1038/nature03180

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., Toan, S. V., Bruijn, L. I., Su, Z.-Z., Gupta, P., & Fisher, P. B.
Affiliations
  • Johns Hopkins University (US)
  • Amyotrophic Lateral Sclerosis Association (US)
  • Columbia University Irving Medical Center (US)
Corresponding author
Rothstein, Jeffrey D.
ORCID
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2005-01
Volume
433
Issue
7021
Pages
73-77
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
DOI
10.1038/nature03180
OpenAlex
W2083204774
Cited by
1,518
References
27
Citations by year
2026: 49 · 2025: 52 · 2024: 47 · 2023: 48 · 2022: 53 · 2021: 55 · 2020: 60 · 2019: 56 · 2018: 52 · 2017: 76 · 2016: 85 · 2015: 84 · 2014: 107 · 2013: 96 · 2012: 98
FWCI
31.20
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Muscular Dystrophy Association
  • Johns Hopkins University
  • Robert Packard Center for ALS Research, Johns Hopkins University
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
Keywords
beta-lactam antibiotics, ceftriaxone, penicillin, GLT-1, glutamate transporters, neuroprotection, glutamate excitotoxicity, amyotrophic lateral sclerosis, ischemic brain injury, motor neuron degeneration, drug repurposing, transcriptional activation, astrocytes
MeSH terms
Animals, Anti-Bacterial Agents, Ceftriaxone, Cell Count, Cells, Cultured, Central Nervous System, Drug Evaluation, Preclinical, Gene Expression Regulation, Mice, Transgenic, Motor Neurons, Penicillins, Promoter Regions, Genetic, RNA, Messenger, United States, United States Food and Drug Administration, Transcriptional Activation, Genes, Reporter, Neuroprotective Agents, Ischemic Preconditioning, Excitatory Amino Acid Transporter 2, beta-Lactams, Mice, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review